Abbott Laboratories Stock News

A spot-check of early morning Q4 reports show some earnings misses and revenue beats; Tesla and others report after the close.

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare

Abbott (ABT) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.03 per share a year ago.

Healthcare multinational Abbott Laboratories (NYSE:ABT) battled negative Covid-19-related comparables in the 2023 financial year, causing an 8.1% fall in group-wide revenues to $40.1 billion. However,

Abbott Laboratories (NYSE: ABT) is trading down in premarket on Wednesday even though it reported solid results for its fiscal fourth quarter. Why is Abbott stock down on Wednesday?

Abbott, a maker of healthcare products, posted fourth-quarter earnings in line with expectations, and beat sales estimates.

Abbott Laboratories on Wednesday reported a fourth-quarter profit that met Wall Street estimates as strong demand for medical devices offset lower-than-expected sales in its pharmaceuticals unit.

Why bother talking about safe-haven stocks for a recession when we already dodged that bullet last year? Tell me you haven't seen a Friday the 13th movie without telling me.

Several expansive companies are expected to post stellar quarterly growth when they report Q4 results on Wednesday, January 24.

Abbott Laboratories (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Beyond analysts' top -and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter e

Abbott (ABT) is successfully continuing the rollout of Alinity, the company's fully integrated and automated molecular diagnostics analyzer.

Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.

AbbVie launched about a decade ago as Abbott's spinoff of its pharmaceuticals business. Both companies have since lifted earnings into the triple digits.

The latest trading day saw Abbott (ABT) settling at $113.92, representing a +0.37% change from its previous close.